☆ 4.5 Article

Current and emerging biological therapies for Chronic rhinosinusitis with nasal polyps with type 2 inflammation

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2023)

Related references

Note: Only part of the references are listed.

Article Otorhinolaryngology

Peripheral eosinophil count and eosinophil-to-lymphocyte ratio are associated with revision sinus surgery

Karina Bayer et al.

Summary: This study found that higher peripheral eosinophil count and higher ELR were associated with revision endoscopic sinus surgery (ESS) in patients with chronic rhinosinusitis (CRS). Preoperative assessment of hematological indices of the peripheral blood may be a valuable indicator of disease severity, facilitating better treatment selection.

EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY (2023)

Add to Collection

Article Otorhinolaryngology

Association of cytokine profile with prior treatment failure and revision surgery in chronic rhinosinusitis

Elizabeth S. Longino et al.

Summary: This study analyzed nasal mucus inflammatory cytokine patterns in patients with chronic rhinosinusitis, and found that specific cytokine levels were associated with disease severity and the number of prior sinus surgeries. IL-5 and IL-13 were found to be elevated in patients with more prior surgeries. Additionally, IL-10, IL-12, and IL-21 levels decreased as the number of prior surgeries increased.

INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY (2023)

Add to Collection

Article Otorhinolaryngology

Predictive factors of revision endoscopic sinus surgery

Cristina Aguiar et al.

Summary: Despite ESS being the standard treatment for CRSwNP, there is still a high recurrence rate of nasal polyps. This study aimed to analyze the impact of ESS in treating CRSwNP and identify predictors for revision surgery.

EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY (2023)

Add to Collection

Editorial Material Immunology

Biomarkers guiding biological therapeutic strategies in chronic rhinosinusitis with nasal polyps: an emerging challenge

Bing Yan et al.

EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2023)

Add to Collection

Article Otorhinolaryngology

EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023*

W. J. Fokkens et al.

Summary: Severe chronic rhinosinusitis with nasal polyps (CRSwNP) is a debilitating disease with significant impact on quality of life, often characterized by type 2 inflammatory reaction and comorbidities like asthma, allergies, and NSAID-Exacerbated Respiratory Disease. The European Forum for Research and Education in Allergy and Airway diseases presents practical guidelines for patients undergoing biologic treatment, including updated criteria for patient selection and recommendations for monitoring drug effects and making treatment decisions. Gaps in current knowledge and unmet needs in the field are also discussed.

RHINOLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Efficacy and safety of CM310 in severe eosinophilic chronic rhinosinusitis with nasal polyps (CROWNS-1): a multicentre, randomised, double-blind, placebo-controlled phase 2 clinical trial

Yuan Zhang et al.

Summary: This study evaluates the efficacy and safety of CM310 in patients with severe eosinophilic chronic rhinosinusitis with nasal polyps (ECRSwNP). The findings suggest that CM310 can reduce nasal polyp size, alleviate nasal congestion, improve sinus CT scores, and significantly relieve daily symptoms and improve quality of life. CM310 also reduces type 2-related biomarkers. Overall, CM310 is an effective additional treatment option for severe ECRSwNP.

ECLINICALMEDICINE (2023)

Add to Collection

Review Immunology

Role of thymic stromal lymphopoietin in allergy and beyond

Risa Ebina-Shibuya et al.

Summary: This article discusses the roles of the cytokine TSLP in infectious diseases, chronic inflammatory diseases, and cancer, emphasizing its regulation of various cell types. TSLP is not only important in allergic diseases but also plays significant roles in other diseases.

NATURE REVIEWS IMMUNOLOGY (2023)

Add to Collection

Article Pharmacology & Pharmacy

Tezepelumab: First Approval

Sheridan M. Hoy

Summary: Thymic stromal lymphopoietin (TSLP) is a cytokine derived from epithelial cells and is involved in the development of asthma. Tezepelumab is a novel monoclonal antibody that inhibits the action of TSLP. It has been approved for the treatment of asthma and is being evaluated for other diseases.

DRUGS (2022)

Add to Collection

Review Allergy

Endotypes of chronic rhinosinusitis: Relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches

Atsushi Kato et al.

Summary: The study of chronic rhinosinusitis (CRS) has shifted from phenotype-based classification to endotype-based classification, identifying three main endotypes that orchestrate the expression of different gene sets. The development of improved methods for endotyping disease is expanding the use of biological therapies, targeting Type 2 inflammation and potentially other inflammatory endotypes in the future.

ALLERGY (2022)

Add to Collection

Article Pharmacology & Pharmacy

A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma

Dave Singh et al.

Summary: The humanized anti-interleukin (IL)-5 monoclonal antibody GSK3511294 demonstrated good tolerability and dose-proportional pharmacokinetics in patients with asthma, leading to significant reductions in blood eosinophil count that were sustained with increasing doses.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2022)

Add to Collection

Editorial Material Allergy

Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis

[Anonymous]

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)

Add to Collection

Article Allergy

Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial

Claus Bachert et al.

Summary: This study assessed the efficacy and safety of benralizumab in treating CRSwNP. The results showed that benralizumab significantly improved NPS and nasal blockage score, and had significant improvement on difficulty with sense of smell score. Subgroup analyses suggested influences of comorbid asthma, number of NP surgeries, sex, body mass index, and baseline blood eosinophil count on treatment effects.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)

Add to Collection

Review Allergy

Mechanisms and pathogenesis of chronic rhinosinusitis

Atsushi Kato et al.

Summary: Chronic rhinosinusitis (CRS) is a heterogeneous disease characterized by inflammation in the upper airways, which can be divided into two main types based on the presence of nasal polyps. The inflammation is characterized by three different endotypes based on the elevation of specific cytokines. The sinonasal epithelium plays a crucial role in the pathogenesis of CRS by acting as a barrier and participating in both innate and adaptive immunity. Further research is needed to fully understand the mechanisms of CRS pathogenesis.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)

Add to Collection

Article Cell Biology

Predictive Values of Serum IL-33 and sST2 in Endotypes and Postoperative Recurrence of Chronic Rhinosinusitis with Nasal Polyps

Yanni Zhang et al.

Summary: This study found that serum IL-33 and sST2 levels were upregulated in CRSwNP patients and were associated with the degree of mucosal eosinophil infiltration and postoperative recurrence. Serum IL-33 and sST2 may serve as objective biomarkers for distinguishing CRSwNP endotypes and predicting recurrence, with their combined use showing better effectiveness.

MEDIATORS OF INFLAMMATION (2022)

Add to Collection

Review Otorhinolaryngology

The roles of eosinophils and interleukin-5 in the pathophysiology of chronic rhinosinusitis with nasal polyps

Philippe Gevaert et al.

Summary: Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with eosinophilic tissue infiltration and elevated levels of interleukin (IL)-5. Eosinophils and IL-5 play important roles in CRSwNP pathology and may serve as biomarkers for NP recurrence.

INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY (2022)

Add to Collection

Review Allergy

Updates in biologic therapy for chronic rhinosinusitis with nasal polyps and NSAID-exacerbated respiratory disease

Xinni Xu et al.

Summary: This review summarizes the recent clinical evidence on the use of biologicals in severe CRSwNP and N-ERD, and proposes a decision-making approach. Biologicals such as omalizumab, dupilumab, mepolizumab, and benralizumab have shown favorable outcomes in patients with difficult-to-control inflammation and persistent symptoms.

ALLERGY (2022)

Add to Collection

Article Allergy

Phase 2 randomized clinical trial of astegolimab in patients with moderate to severe atopic dermatitis

Marcus Maurer et al.

Summary: In patients with atopic dermatitis, astegolimab did not show a significant difference compared to placebo for the primary or secondary outcomes.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)

Add to Collection

Article Allergy

Isolation, identification, and characterization of the human airway ligand for the eosinophil and mast cell immunoinhibitory receptor Siglec-8

Anabel Gonzalez-Gil et al.

Summary: The study identified a high molecular weight Siglec-8 ligand on the mucus layer of human airways, composed of DMBT1S8 with picomolar affinity for Siglec-8. This finding is important for understanding the pathogenesis and treatment of airway diseases.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)

Add to Collection

Review Otorhinolaryngology

International consensus statement on allergy and rhinology: rhinosinusitis 2021

Richard R. Orlandi et al.

Summary: The executive summary of ICAR-RS-2021 compiles evidence-based recommendations for medical and surgical treatment of rhinologic diseases, covering both medical and surgical management with a comprehensive management algorithm.

INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY (2021)

Add to Collection

Article Allergy

Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): A randomized double-blind placebo-controlled trial

Jody Tversky et al.

Summary: Inhibiting the IL-5 receptor using benralizumab showed significant improvement in nasal polyp score, reduction in polyp size, and improvement in symptoms and smell sensation for most patients with severe rhinosinusitis with nasal polyps.

CLINICAL AND EXPERIMENTAL ALLERGY (2021)

Add to Collection

Review Allergy

Highlights in the advances of chronic rhinosinusitis

Xinni Xu et al.

Summary: Endotyping is now favored over phenotype-based classifications in the management of Chronic Rhinosinusitis (CRS), particularly in challenging cases with nasal polyposis. The latest update from EPOS2020 includes revised classifications and care pathways for rhinosinusitis. Balancing the responsibility of managing patients' upper airway while protecting themselves from droplet and aerosol transmission is crucial for physicians and rhinologists during the COVID-19 pandemic.

ALLERGY (2021)

Add to Collection

Article Otorhinolaryngology

A Phase II, Multicenter, Randomized, Placebo-Controlled Study of Benralizumab, a Humanized Anti-IL-5R Alpha Monoclonal Antibody, in Patients With Eosinophilic Chronic Rhinosinusitis

Tetsuji Takabayashi et al.

Summary: This study conducted in Japan enrolled a total of 56 patients. Results showed that although benralizumab did not meet the primary efficacy endpoint, reductions in nasal polyp scores were seen in the benralizumab group compared with the placebo group over the whole study period, especially in patients with high levels of blood eosinophils.

AMERICAN JOURNAL OF RHINOLOGY & ALLERGY (2021)

Add to Collection

Article Allergy

Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial

Steven G. Kelsen et al.

Summary: The study evaluated the efficacy and safety of Astegolimab in patients with severe asthma, showing that the drug reduced asthma exacerbation rate and had a good effect on patients with low blood eosinophils, while maintaining safety and tolerability.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)

Add to Collection

Article Critical Care Medicine

Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial

Joseph K. Han et al.

Summary: The study aimed to evaluate the efficacy and safety of mepolizumab in adults with recurrent, refractory severe bilateral chronic rhinosinusitis with nasal polyps. Results showed that mepolizumab treatment significantly improved nasal polyp size and nasal obstruction symptoms, with fewer adverse events.

LANCET RESPIRATORY MEDICINE (2021)

Add to Collection

Letter Critical Care Medicine

Do B cells rather than eosinophils drive chronic rhinosinusitis with nasal polyps

Harsha H. Kariyawasam et al.

LANCET RESPIRATORY MEDICINE (2021)

Add to Collection

Article Critical Care Medicine

Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial

Sarah Diver et al.

Summary: Tezepelumab demonstrates efficacy in reducing airway eosinophil counts and improving airway hyperresponsiveness in patients with severe uncontrolled asthma, regardless of baseline blood eosinophil count.

LANCET RESPIRATORY MEDICINE (2021)

Add to Collection

Article Otorhinolaryngology

Predictive markers of long-term recurrence in chronic rhinosinusitis with nasal polyps

Rosati Davide et al.

AMERICAN JOURNAL OF OTOLARYNGOLOGY (2020)

Add to Collection

Article Otorhinolaryngology

Revision surgery rates in chronic rhinosinusitis with nasal polyps: meta-analysis of risk factors

Catherine A. Loftus et al.

INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY (2020)

Add to Collection

Review Allergy

Biologics in chronic rhinosinusitis with nasal polyposis

Tanya M. Laidlaw et al.

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2020)

Add to Collection

Review Immunology

The epithelium-derived inflammatory mediators of chronic rhinosinusitis with nasal polyps

Chengshuo Wang et al.

EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2020)

Add to Collection

Article Otorhinolaryngology

Long-term outcomes of different endoscopic sinus surgery in recurrent chronic rhinosinusitis with nasal polyps and asthma

Luo Zhang et al.

RHINOLOGY (2020)

Add to Collection

Article Otorhinolaryngology

T helper 2 inflammatory markers are associated with recurrence in chronic rhinosinusitis with nasal polyps after endoscopic sinus surgery

Geoffrey Mortuaire et al.

RHINOLOGY (2020)

Add to Collection

Review Allergy

Role of IL-25, IL-33, and TSLP in triggering united airway diseases toward type 2 inflammation

Haiyu Hong et al.

ALLERGY (2020)

Add to Collection

Article Allergy

Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials

Philippe Gevaert et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)

Add to Collection

Review Immunology

Chronic rhinosinusitis with nasal polyps: mechanistic insights from targeting IL-4 and IL-13 via IL-4Rα inhibition with dupilumab

Harsha H. Kariyawasam

EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2020)

Add to Collection

Review Critical Care Medicine

Group 2 Innate Lymphoid Cells in Airway Diseases

Atsushi Kato

CHEST (2019)

Add to Collection

Article Medicine, General & Internal

Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

Claus Bachert et al.

LANCET (2019)

Add to Collection

Review Cardiac & Cardiovascular Systems

Eosinophils, the IL-5/IL-5Rα axis, and the biologic effects of benralizumab in severe asthma

Andrea Matucci et al.

RESPIRATORY MEDICINE (2019)

Add to Collection

Article Otorhinolaryngology

Revision endoscopic sinus surgery rates by chronic rhinosinusitis subtype

Amar Miglani et al.

INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY (2018)

Add to Collection

Review Pharmacology & Pharmacy

Chronic rhinosinusitis: pathogenesis, therapy options, and more

Umut Can Kucuksezer et al.

EXPERT OPINION ON PHARMACOTHERAPY (2018)

Add to Collection

Article Allergy

Nasal and sinus symptoms and chronic rhinosinusitis in a population-based sample

A. G. Hirsch et al.

ALLERGY (2017)

Add to Collection

Article Otorhinolaryngology

The role of IL-25 and IL-33 in chronic rhinosinusitis with or without nasal polyps

Atakan Ozturan et al.

EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY (2017)

Add to Collection

Article Medicine, Research & Experimental

Prevalence of Polyp Recurrence After Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyposis

Adam S. DeConde et al.

LARYNGOSCOPE (2017)

Add to Collection

Article Respiratory System

The role of interleukin-33 in chronic rhinosinusitis

Dong-Kyu Kim et al.

THORAX (2017)

Add to Collection

Review Immunology

IL-33: biological properties, functions, and roles in airway disease

Li Yin Drake et al.

IMMUNOLOGICAL REVIEWS (2017)

Add to Collection

Article Allergy

Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial

Claus Bachert et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)

Add to Collection

Review Allergy

Regulation of airway inflammation by Siglec-8 and Siglec-9 sialoglycan ligand expression

Robert P. Schleimer et al.

CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY (2016)

Add to Collection

Article Pharmacology & Pharmacy

Reslizumab: First Global Approval

Anthony Markham

DRUGS (2016)

Add to Collection

Article Medicine, General & Internal

Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis A Randomized Clinical Trial

Claus Bachert et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)

Add to Collection

Article Allergy

Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers

Peter Tomassen et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)

Add to Collection

Review Allergy

Chronic Rhinosinusitis with Nasal Polyps

Whitney W. Stevens et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2016)

Add to Collection

Article Allergy

Interaction of thymic stromal lymphopoietin, IL-33, and their receptors in epithelial cells in eosinophilic chronic rhinosinusitis with nasal polyps

B. Liao et al.

ALLERGY (2015)

Add to Collection

Article Otorhinolaryngology

Interleukin-25 and interleukin-33 as mediators of eosinophilic inflammation in chronic rhinosinusitis

Matthew Lam et al.

AMERICAN JOURNAL OF RHINOLOGY & ALLERGY (2015)

Add to Collection

Article Pharmacology & Pharmacy

Monoclonal Antibodies in Allergy; Updated Applications and Promising Trials

Cevdet Ozdemir

RECENT PATENTS ON INFLAMMATION & ALLERGY DRUG DISCOVERY (2015)

Add to Collection

Article Otorhinolaryngology

Differences in initial immunoprofiles between recurrent and nonrecurrent chronic rhinosinusitis with nasal polyps

Thibaut Van Zele et al.

AMERICAN JOURNAL OF RHINOLOGY & ALLERGY (2014)

Add to Collection

Article Medicine, Research & Experimental

Expression of IL-33 and its receptor ST2 in chronic rhinosinusitis with nasal polyps

Shintaro Baba et al.

LARYNGOSCOPE (2014)

Add to Collection

Review Immunology

Siglec-mediated regulation of immune cell function in disease

Matthew S. Macauley et al.

NATURE REVIEWS IMMUNOLOGY (2014)

Add to Collection

Article Allergy

Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma

Philippe Gevaert et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)

Add to Collection

Article Allergy

Thymic stromal lymphopoietin activity is increased in nasal polyps of patients with chronic rhinosinusitis

Deepti R. Nagarkar et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)

Add to Collection

Article Otorhinolaryngology

Clinical Characteristics and Expression of Thymic Stromal Lymphopoetin in Eosinophilic and Non-Eosinophilic Chronic Rhinosinusitis

Yuhui Ouyang et al.

ORL-JOURNAL FOR OTO-RHINO-LARYNGOLOGY HEAD AND NECK SURGERY (2013)

Add to Collection

Article Allergy

Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis

Philippe Gevaert et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2011)

Add to Collection

Article Allergy

MEDI-563, a humanized anti-IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function

Roland Kolbeck et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)

Add to Collection

Review Immunology

IL-5-and eosinophil-mediated inflammation: from discovery to therapy

Taku Kouro et al.

INTERNATIONAL IMMUNOLOGY (2009)

Add to Collection

Article Allergy

IL-33-activated dendritic cells induce an atypical TH2-type response

Matthew A. Rank et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2009)

Add to Collection

Article Allergy

Inhibition of FcεRI-dependent mediator release and calcium flux from human mast cells by sialic acid-binding immunoglobulin-like lectin 8 engagement

Hidenori Yokoi et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2008)

Add to Collection

Article Allergy

Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps

Philippe Gevaert et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2006)

Add to Collection

Article Immunology

IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines

J Schmitz et al.

IMMUNITY (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.